Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02)

Clinical Cancer Research

Volumn 18, Issue 18, 2012, Pages 5123-5133

  Thariat, Juliette ^a,b,c   Bensadoun, René Jean ^d   Etienne Grimaldi, Marie Christine ^b   Grall, Dominique ^c   Penault Llorca, Frédérique ^e   Dassonville, Olivier ^b   Bertucci, Francois ^f   Cayre, Anne ^e   De Raucourt, Dominique ^g   Geoffrois, Lionnel ^h   Finetti, Pascal ^f   Giraud, Philippe ⁱ   Racadot, Séverine ^j   Morinière, Sylvain ^k   Sudaka, Anne ^b   Van Obberghen Schilling, Ellen ^a,c   Milano, Gérard ^b  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c CENTRE DE BIOCHIMIE   (France)

^d POITIERS UNIVERSITY HOSPITAL   (France)

^e CENTRE JEAN PERRIN   (France)

^f INSTITUT PAOLI CALMETTES   (France)

^g CENTRE FRANÇOIS BACLESSE   (France)

^h CENTRE ALEXIS VAUTRIN   (France)

ⁱ INSTITUT CURIE   (France)

^j CENTRE LÉON BÉRARD   (France)

^k UNIVERSITY HOSPITAL OF TOURS   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CISPLATIN; GEFITINIB; P21 ACTIVATED KINASE 1; PLACEBO; SOMATOMEDIN C RECEPTOR;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CHEMORADIOTHERAPY; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84866423991     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-1518     Document Type: Article

References (51)

1. Bernier J, Vermorken JB, Koch WM. Adjuvant therapy in patients with resected poor-risk head and neck cancer. J Clin Oncol 2006;24:2629-35.
2. Santini J, Formento JL, Francoual M, Milano G, Schneider M, Dassonville O, et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991;13:132-9.
3. Dassonville O, Formento J, Francoual M, Ramaioli A, Santini J, Schneider M, et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993;11:1873-8.
4. Grandis JR, Tweardy DJ. Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
5. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002;62:7350-6.
6. Liang K, Ang KK, Milas L, Hunter N, Fan Z. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003;57:246-54.
7. Thariat J, Milas L, Ang KK. Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 2007;69:974-84.
8. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
9. Magne N, Fischel JL, Dubreuil A, Formento P, Marcie S, Lagrange JL, et al. Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 2002;86:819-27.
10. Magne N, Fischel JL, Dubreuil A, Formento P, Poupon MF, Laurent-Puig P, et al. Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa"). Br J Cancer 2002;86:1518-23.
11. Bozec A, Formento P, Ciccolini J, Fanciullino R, Padovani L, Murraciole X, et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther 2005;4:1962-71.
12. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol 2004;15:1007-12.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2005;2:416-22.
14. Formento JL, Francoual M, Formento P, Etienne MC, Fischel JL, Namer M, et al. Epidermal growth factor receptor assay: validation of a single point method and application to breast cancer. Breast Cancer Res Treat 1991;17:211-9.
15. Thariat J, Etienne-Grimaldi MC, Grall D, Bensadoun RJ, Cayre A, Penault-Llorca F, et al. Epidermal growth factor receptor protein detection in head and neck cancer patients: a many-faceted picture. Clin Cancer Res 2012;18:1313-22.
16. Thariat J, de Raucourt D, Giraud P, Peyrade F, Dassonville O, Cosmidis A, et al. Compliance and toxicity profiles of the CARISSA trial of postoperative cisplatin-based chemoradiation ± gefitinib in head and neck cancer. J Clin Oncol (Meeting Abstracts) 2009;27:e22152.
17. Thariat J, Grall D, Etienne-Grimaldi MC, Penault-Llorca F, Francoual M, Milano G, et al. Correlative analyses between EGFR pathways and stroma-tumor profiles in head and neck cancer patients (HNSCC) on postoperative radiotherapy plus cisplatin (PORTc) plus or minus gefitinib (GORTEC-GETTEC CARISSA trial): implications for sensitivity to gefitinib. J Clin Oncol 28:15s, 2010 (suppl; abstr TPS268).
18. Xu H, Stabile LP, Gubish CT, Gooding WE, Grandis JR, Siegfried JM. Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells. Clin Cancer Res 2011;17:4425-38.
19. Zhang Q,Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-73.
20. Van Waes C, Allen CT, Citrin D, Gius D, Colevas AD, Harold NA, et al. Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2010;77:447-54.
21. Tan EH, Goh C, Lim WT, Soo KC, Khoo ML, Tan T, et al. Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers. Ann Oncol 2012;23:1010-6.
22. Chen C, Kane M, Song J, Campana J, Raben A, Hu K, et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J Clin Oncol 2007;25:4880-6.
23. Cohen EE, Haraf DJ, Kunnavakkam R, Stenson KM, Blair EA, Brockstein B, et al. Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2010;28:3336-43.
24. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, Witt ME, et al. Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: a multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008;19:1787-94.
25. Hainsworth JD, Spigel DR, Burris HA III, Markus TM, Shipley D, Kuzur M, et al. Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck. Cancer 2009;115:2138-46.
26. Gregoire V, Hamoir M, Chen C, Kane M, Kawecki A, Julka PK, et al. Ge fitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study. Radiother Oncol 2011;100:62-9.
27. Pernas FG, Allen CT, Winters ME, Yan B, Friedman J, Dabir B, et al. Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer. Clin Cancer Res 2009;15:2361-72.
28. Sharp H, Morris JC, Van Waes C, Gius D, Cooley-Zgela T, Singh AK. High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent externalbeam radiation for locally advanced head and neck cancers. Am J Clin Oncol 2008;31:557-60.
29. Zhang S, Chen J, Jiang H, Ma H, Yang B. Anti-epidermal growth factor receptor therapy for advanced head and neck squamous cell carcinoma: a meta-analysis. Eur J Clin Pharmacol 2012;68:561-9.
30. Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35.
31. Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009;28:51-63.
32. Barnes CJ, Bagheri-Yarmand R, Mandal M, Yang Z, Clayman GL, Hong WK, et al. Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa). Mol Cancer Ther 2003;2:345-51.
33. Tu HF, Chang KW, Chiang WF, Liu CJ, Yu EH, Liu ST, et al. The frequent co-expression of the oncogenes PIK3CA and PAK1 in oral carcinomas. Oral Oncol 2011;47:211-6.
34. Barnes CJ, Ohshiro K, Rayala SK, El-Naggar AK, Kumar R. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer. Clin Cancer Res 2007;13:4291-9.
35. Lara PC, Bordon E, Rey A, Moreno M, Lloret M, Henriquez-Hernandez LA. IGF-1R expression predicts clinical outcome in patients with locally advanced oral squamous cell carcinoma. Oral Oncol 2011;47:615-9.
36. Milas L, Akimoto T, Hunter NR, Mason KA, Buchmiller L, Yamakawa M, et al. Relationship between cyclin D1 expression and poor radio-response of murine carcinomas. Int J Radiat Oncol Biol Phys 2002;52:514-21.
37. Frederick BA, Helfrich BA, Coldren CD, Zheng D, Chan D, Bunn PA Jr, et al. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther 2007;6:1683-91.
38. Brehmer D, Greff Z, Godl K, Blencke S, Kurtenbach A, Weber M, et al. Cellular targets of gefitinib. Cancer Res 2005;65:379-82.
39. Ahmad T, Farnie G, Bundred NJ, Anderson NG. The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. J Biol Chem 2004;279:1713- 9.
40. Huang F, Xu LA, Khambata-Ford S. Correlation between gene expression of IGF-1R pathway markers and cetuximab benefit in metastatic colorectal cancer. Clin Cancer Res 2012;18:1156-66.
41. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004;11:793-814.
42. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-8.
43. Chandarlapaty S, Sawai A, Scaltriti M, Rodrik-Outmezguine V, Grbovic-Huezo O, Serra V, et al. AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. Cancer Cell 2011;19:58-71.
44. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007;6:667-74.
45. Lacouture ME, O'Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell carcinomas byRAF inhibitors: cause for concern? J Clin Oncol 2012;30:329-30.
46. Dahan L, Sadok A, Formento JL, Seitz JF, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol 2009;158:610-20.
47. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009;27:1130-6.
48. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J Clin Oncol 2008;26:983-94.
49. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6.
50. Winder T, Zhang W, Yang D, Ning Y, Bohanes P, Gerger A, et al. Germline polymorphisms in genes involved in the IGF1 pathway predict efficacy of cetuximab in wild-type KRAS mCRC patients. Clin Cancer Res 2010;16:5591-602.
51. Jimeno A, Kulesza P, Wheelhouse J, Chan A, Zhang X, Kincaid E, et al. Dual EGFR and mTOR targeting in squamous cell carcinoma models, and development of early markers of efficacy. Br J Cancer 2007;96:952-9.